Pressure BioSciences (OTCQB: PBIO), a leader in the
development and sale of broadly enabling, pressure-based technology and
products to the worldwide life sciences and other industries, this morning
announced that its flagship Barocycler 2320EXTREME was prominently featured at
a three-day, internationally-attended scientific conference held at the elite
Westlake University in Hangzhou, China. Professor Tiannan Guo, MD., PhD, a
well-known protein research scientist, was one of the primary conference
organizers. Professor Guo’s Westlake laboratory was named a PBI Center of
Excellence in 2017. “Many of the studies on cancer biopsy tissues performed at
Westlake and in the laboratories of our collaboration partners rely critically
on PBI’s PCT platform to rapidly and reproducibly extract high quality proteins
from tumor tissues for analysis by mass spectrometry,” Professor Guo stated in
the news release. “It is hoped that such activities will eventually result in
the discovery of new biomarkers of disease and possibly even new drug targets.”
To view the full press release, visit http://ibn.fm/IosQ2
About Pressure BioSciences Inc.
Pressure BioSciences (OTCQB: PBIO) is a leader in the
development and sale of innovative, broadly enabling, pressure-based solutions
for the worldwide life sciences industry. The company’s products are based on
the unique properties of both constant (i.e., static) and alternating (i.e.,
pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented
enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to safely and reproducibly
control biomolecular interactions (e.g., cell lysis, biomolecule extraction).
PBIO’s primary focus is in the development of PCT-based products for biomarker
and target discovery, drug design and development, biotherapeutics
characterization and quality control, soil and plant biology, forensics and
counter-bioterror applications. Additionally, major new market opportunities have
emerged in the use of its pressure-based technologies in the following areas:
(1) the use of its recently acquired PreEMT technology from BaroFold Inc. to
allow entry into the biologics contract research services sector, and (2) the
use of its recently patented, scalable, high-efficiency, pressure-based Ultra
Shear Technology (“UST”) platform to (i) create stable nanoemulsions of
otherwise immiscible fluids (e.g., oils and water) and (ii) prepare higher
quality, homogenized, extended shelf-life or room temperature stable low-acid
liquid foods that cannot be effectively preserved using existing non-thermal
technologies. For more information, visit the company’s website at www.PressureBiosciences.com.
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news breaks
keep you up-to-date with the day’s top movers. MissionIR is primarily focused
on strategic communications. We have executed countless communications programs
to address the needs of companies ranging from start-ups to established
industry leaders, gaining valuable experience and the expertise necessary to
determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
